HUTCHMED (HCM) Stock Price, News & Analysis

Company Overview

HUTCHMED (NASDAQ: HCM) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for oncology and autoimmune diseases. Founded in 2000, the company leverages an integrated research and development platform spanning molecular biology, medicinal chemistry and translational research to advance novel small molecules and biologics from laboratory through clinical trials. HUTCHMED’s goal is to address high‐unmet medical needs by developing precision medicines that improve outcomes for patients with challenging cancers and inflammatory disorders.

HUTCHMED’s portfolio includes marketed products such as fruquintinib, an oral VEGFR inhibitor approved in China for colorectal cancer, and surufatinib, a multi‐kinase inhibitor approved for neuroendocrine tumors. The company’s pipeline encompasses a diverse set of targeted therapies in various stages of clinical development, including novel kinase inhibitors, antibody–drug conjugates and checkpoint modulators. Strategic collaborations with global pharmaceutical partners support the advancement of lead programs into late‐stage trials and facilitate broader regulatory filings.

With headquarters in Shanghai and Hong Kong, HUTCHMED operates research sites, manufacturing facilities and commercial teams across Greater China and maintains partnerships to expand its footprint in North America, Europe and other key markets. The company’s operations are underpinned by a seasoned management team and Board whose collective experience spans drug discovery, clinical development and global commercialization. HUTCHMED continues to invest in scientific innovation and infrastructure to strengthen its position as a leading China‐based R&D organization with a growing international presence.

Key Stats

• Today's Range: $17.58 to $17.97
• 50-Day Range: $13.09 to $17.72
• 52-Week Range: $11.51 to $21.50
• Volume: 25,725 shs
• Average Volume: 91,350 shs
• Market Capitalization: $3.07 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.00
• Consensus Rating: Hold

HUTCHMED Stock Analysis - MarketRank™

HUTCHMED scored higher than 16% of companies evaluated by MarketBeat, and ranked 851st out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

HUTCHMED has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

HUTCHMED has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 812.50%

Earnings Growth

Earnings for HUTCHMED are expected to grow by 812.50% in the coming year, from $0.16 to $1.46 per share.

Price to Book Value per Share Ratio

HUTCHMED has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.25% of the float of HUTCHMED has been sold short.

Short Interest Ratio / Days to Cover

HUTCHMED has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in HUTCHMED has recently decreased by 4.55%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HUTCHMED does not currently pay a dividend.

Dividend Growth

HUTCHMED does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.25% of the float of HUTCHMED has been sold short.

Short Interest Ratio / Days to Cover

HUTCHMED has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in HUTCHMED has recently decreased by 4.55%, indicating that investor sentiment is improving.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HUTCHMED insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.60% of the stock of HUTCHMED is held by insiders.

Percentage Held by Institutions

Only 8.82% of the stock of HUTCHMED is held by institutions.

HCM Stock Analysis - Frequently Asked Questions

How have HCM shares performed this year?

HUTCHMED's stock was trading at $14.41 on January 1st, 2025. Since then, HCM shares have increased by 22.1% and is now trading at $17.59.

When did HUTCHMED IPO?

HUTCHMED (HCM) raised $100 million in an initial public offering on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

Who are HUTCHMED's major shareholders?

HUTCHMED's top institutional investors include Janney Capital Management LLC (0.01%).

How do I buy shares of HUTCHMED?

Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

• Today: 7/19/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HCM
• CIK: 1648257
• Web: www.chi-med.com
• Phone: 852-2121-3888
• Fax: 852-2128-1778
• Employees: 1,811
• Year Founded: 2000

Price Target and Rating

• Average Price Target for HUTCHMED: $19.00
• High Price Target: $19.00
• Low Price Target: $19.00
• Potential Upside/Downside: +8.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 2.83
• Quick Ratio: 2.70

Sales & Book Value

• Annual Sales: $630.20 million
• Price / Sales: 4.87
• Cash Flow: $0.29 per share
• Price / Cash Flow: 61.00
• Book Value: $4.43 per share
• Price / Book: 3.97

Miscellaneous

• Outstanding Shares: 174,422,000
• Free Float: 168,143,000
• Market Cap: $3.07 billion
• Optionable: Not Optionable
• Beta: 0.52